Thrombolex, Inc. — SEC Form D Filing
Thrombolex, Inc. filed an SEC Form D on March 12, 2026, reporting $32.77M raised in Health Care.
Form D filing details
- Filing
- SEC Form D
- Filing date
- March 12, 2026
- Amount reported
- $32.77M
- Round stage
- Series A
- Industry
- Health Care
- Website
- https://thrombolex.com/
What the company does
Securities: Equity, Includes Conversion of Outstanding Notes. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Treating arterial and venous thromboembolic conditions safely and effectively while minimizing risk and maximizing clot burden resolution is critical.
Solution
The BASHIR™ family of endovascular catheters uses a hybrid mechanism of action combining mechanical and pharmacological therapy to restore blood flow and efficiently introduce thrombolytics.
Why now
The rise in awareness and occurrence of thromboembolic conditions necessitates innovative treatments to improve patient outcomes.
Verdict
": "Investors backed Thrombolex because the BASHIR™ catheters presented a unique solution to a growing health problem, not because existing treatments were insufficiently competitive. They implicitly bet on the urgency for innovative approaches in vascular therapy due to rising thromboembolic conditions. However, this bet carries limited upside as market traction depends heavily on acceptance from conservative medical professionals wary of new technology.", "Signal Cards": { "Narrative Clarity": "High — The company’s mission and solution are well defined, making it easier to price the round.", "Market Legibility": "Medium — While the market for thrombolytic therapies is clear, specific dynamics around adoption remain uncertain.", "Differentiation": "High — The hybrid mechanism of action sets Thrombolex apart from traditional solutions, aiding valuation.", "Defensibility": "Moderate — Adoption relies on clinical outcomes and acceptance, which could jeopardize long-term market protection." }, "Narrative Fingerprint": { "Clear buyer identified": "Yes (Strong)", "Budget owner named": "Yes (Strong)", "Cost replacement articulated": "Yes (Strong)", "Regulatory tailwinds present": "No", "Technological novelty": "Yes (Moderate)", "Expansion narrative beyond wedge": "No" }, "Competitive Narrative Context": { "Crowded themes": [ "Vascular health advancements", "Interventional therapy innovations", "Emphasis on patient outcomes" ], "Differentiation warnings": [ "Relevant concerns about the risks associated with new technologies", "Market skepticism towards efficacy of hybrid systems", "Potential for traditional brands to introduce similar innovations" ], "White-space opportunities": [ "Emerging focus on shorter recovery times in thromboembolic interventions", "Increasing integration of technology in routine surgical procedures", "Growing reform in healthc
Source: SEC EDGAR Form D filing